Centerspace CSR
REAL ESTATE · REIT - RESIDENTIALi
Market dataready · fetched 2026-11-11T13:46:58.837Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T00:00:00.002975816Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:42:13.791799+00:00
Centerspace options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 48.76 | 139.8% | 18.0% | |||
| 25Δ | 76.83 | 213.8% | 38.7% | 49.95 | 155.3% | 16.9% |
| 30Δ | 52.05 | 131.7% | 13.2% | |||
| 35Δ | 59.04 | 41.9% | 5.0% | 54.19 | 106.4% | 9.5% |
| 40Δ | 58.54 | 41.5% | 4.5% | 55.33 | 92.4% | 7.6% |
| 45Δ | 58.04 | 41.1% | 4.0% | 55.87 | 85.2% | 6.7% |
| 50Δ | 57.54 | 40.7% | 3.5% | 56.40 | 78.1% | 5.9% |
| 55Δ | 57.03 | 40.3% | 3.0% | 56.94 | 71.0% | 5.1% |
| 60Δ | 56.53 | 39.9% | 2.5% | 57.47 | 63.8% | 4.2% |
| 65Δ | 56.03 | 39.5% | 2.0% | 58.00 | 56.7% | 3.4% |
| 70Δ | 55.53 | 39.1% | 1.5% | 58.54 | 49.5% | 2.6% |
| 75Δ | 55.03 | 38.7% | 1.0% | 59.07 | 42.4% | 1.7% |
| 80Δ | 53.95 | 39.7% | 0.8% | 59.61 | 35.3% | 0.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 48.76
- IV
- 139.8%
- B/E move
- 18.0%
25Δ
- Pseudo strike
- 76.83
- IV
- 213.8%
- B/E move
- 38.7%
- Pseudo strike
- 49.95
- IV
- 155.3%
- B/E move
- 16.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 52.05
- IV
- 131.7%
- B/E move
- 13.2%
35Δ
- Pseudo strike
- 59.04
- IV
- 41.9%
- B/E move
- 5.0%
- Pseudo strike
- 54.19
- IV
- 106.4%
- B/E move
- 9.5%
40Δ
- Pseudo strike
- 58.54
- IV
- 41.5%
- B/E move
- 4.5%
- Pseudo strike
- 55.33
- IV
- 92.4%
- B/E move
- 7.6%
45Δ
- Pseudo strike
- 58.04
- IV
- 41.1%
- B/E move
- 4.0%
- Pseudo strike
- 55.87
- IV
- 85.2%
- B/E move
- 6.7%
50Δ
- Pseudo strike
- 57.54
- IV
- 40.7%
- B/E move
- 3.5%
- Pseudo strike
- 56.40
- IV
- 78.1%
- B/E move
- 5.9%
55Δ
- Pseudo strike
- 57.03
- IV
- 40.3%
- B/E move
- 3.0%
- Pseudo strike
- 56.94
- IV
- 71.0%
- B/E move
- 5.1%
60Δ
- Pseudo strike
- 56.53
- IV
- 39.9%
- B/E move
- 2.5%
- Pseudo strike
- 57.47
- IV
- 63.8%
- B/E move
- 4.2%
65Δ
- Pseudo strike
- 56.03
- IV
- 39.5%
- B/E move
- 2.0%
- Pseudo strike
- 58.00
- IV
- 56.7%
- B/E move
- 3.4%
70Δ
- Pseudo strike
- 55.53
- IV
- 39.1%
- B/E move
- 1.5%
- Pseudo strike
- 58.54
- IV
- 49.5%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 55.03
- IV
- 38.7%
- B/E move
- 1.0%
- Pseudo strike
- 59.07
- IV
- 42.4%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 53.95
- IV
- 39.7%
- B/E move
- 0.8%
- Pseudo strike
- 59.61
- IV
- 35.3%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 29.68% | |
| 32.06% | |
| 30.39% | |
| 32.32% | |
| 34.43% | |
| 33.03% | |
| 35.91% | |
| 29.99% |
Reit - Residential
ELME
Description unavailable
More →ELS
We are a self-managed and self-managed real estate investment trust (?
More →ESS
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments, primarily on the West Coast of the United States.
More →INVH
Invitation Homes is the nation's leading single-family home leasing company, meeting changing lifestyle demands by providing access to high-quality, renovated homes with valuable…
More →IRT
Independence Realty Trust, Inc. (NYSE: IRT) is a real estate investment trust that owns and operates multi-family apartment properties in non-entry US markets, including Atlanta,…
More →JAN
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and…
More →